Artesunate

Artesunate Injection can be administered by intravenous injection or by intramuscular by a healthcare professional. Kindly do not self administer. It is prescribed in cases where an oral administration is not appropriate.
In case you miss artesunate injection dosage, please consult your healthcare practitioner.

Most common adverse reactions include body ache, headache, bradycardia, abdominal pain, nausea, dizziness, vomiting, and diarrhoea.

• Care should be implemented in those patients who are with the hepatic impairment due to the potential hepatotoxic effects.
• Patients should be monitored for 4 weeks following treatment with the inj falcigo for the evidence of hemolytic anemia.
• In order to delay the treatment of severe malaria during pregnancy may be responsible for serious morbidity and mortality to the mother as well as fetus.
• Patients should be advised of the need to complete the appropriate oral antimalarial therapy following treatment with artesunate 120 mg injection.
• Patients should be instructed of the need for the regular blood tests for the 4-week period after completion of treatment in order to monitor for the post-treatment delayed hemolysis.
• It is advised that the renal function, glucose, hepatic/haematological function is monitored throughout the treatment.
• Patients should be monitored for signs of toxicity such as neurological symptoms, persistent vomiting/rash.
  Women with falcigo 120 mg should discuss with their healthcare provider prior to starting breastfeeding and conceiving a baby.

Care should be exercised in the handling of ARTESUNATE. ARTESUNATE injections should not be opened or crushed. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze it and avoid exposure to heat. Keep protected from the light. Avoid using beyond the expiration date.

• The concomitant administration of Artesunate injection with oral ritonavir, nevirapine, or UGT inducers may reduce dihydroartemisinin (DHA) AUC and Cmax, which may decrease the efficacy of Artesunate Injection. If Artesunate is co-administered with ritonavir, nevirapine, or strong UGT inducers (e.g., rifampin, phenytoin, carbamazepine), evaluate for possible reduced antimalarial efficacy of Artesunate.
• The concomitant use of Artesunate with UGT inhibitors may increase DHA AUC and Cmax, which may increase the DHA-associated side effects. Monitor for side effects when co-administering Artesunate with strong UGT inhibitors (e.g., axitinib, imatinib, vandetanib, diclofenac).